Understanding the Metabolic Syndrome Using a Biomedical Chemistry Profile

Pereira, Cidália; Monteiro, Rosário; Martins, Maria João

http://hdl.handle.net/10400.8/15057

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Understanding the Metabolic Syndrome Using a Biomedical Chemistry Profile.pdf		110.34 KB	Adobe PDF	Download

Send Feedback

Authors

Pereira, Cidália

Monteiro, Rosário

Martins, Maria João

Abstract(s)

2.3.1 Introduction For quite some time, it has been identified that high blood pressure, dyslipidemia [increased triglycerides and reduced high-density lipoprotein (HDL) cholesterol levels], impaired glucose homeostasis and abdominal obesity take place concurrently more than by random, supporting the existence of the metabolic syndrome (MetSyn). Additionally, hyperuricemia, a prothrombotic state, oxidative stress, chronic low grade inflammation, increased levels of apolipoprotein-B and small dense low density lipoprotein (LDL) cholesterol (contributing to atherogenic dyslipidemia), non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, obstructive sleep apnea and/or polycystic ovarian disease (Fulop, 2006; Alberti, 2009; Roberts, 2009; Ma, 2012; Matsuda, 2013; Mule, 2014; Carson, 2015) are quite often present on the MetSyn, although not yet included in its current/actual definition. Taking this into consideration, it is not surprising that the MetSyn associates with an increased risk of type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (Fulop, 2006; Qiao, 2007; Carson, 2015).

Keywords

Metabolic Syndrome

URI

http://hdl.handle.net/10400.8/15057

Citation

Pereira, C., Monteiro, R. & João Martins, M. (2015). 2.3 Understanding the Metabolic Syndrome Using a Biomedical Chemistry Profile. In Biomedical Chemistry: Current Trends and Developments (pp. 132-147). Warsaw, Poland: De Gruyter Open Poland. https://doi.org/10.1515/9783110468755-005